Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.

[1]  N. Fortunati,et al.  Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer , 2012, Front. Endocrin..

[2]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[3]  S. Franceschi,et al.  Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis. , 2012, Thyroid : official journal of the American Thyroid Association.

[4]  J. Tabernero,et al.  Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. , 2011, Future oncology.

[5]  V. de Giorgi,et al.  Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[6]  Z. Barekati,et al.  Cell-free DNA in the circulation as a potential cancer biomarker. , 2011, Anticancer research.

[7]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[8]  Y. Nikiforov.  Molecular diagnostics of thyroid tumors. , 2011, Archives of pathology & laboratory medicine.

[9]  C. Nucera,et al.  BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. , 2011, Cancer research.

[10]  E. Urso,et al.  Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy , 2011, Annals of Surgical Oncology.

[11]  A. Toniato,et al.  BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience , 2011, Clinical chemistry and laboratory medicine.

[12]  K. Jung,et al.  Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[13]  M. Fournier,et al.  A need for basic research on fluid-based early detection biomarkers. , 2010, Cancer research.

[14]  M. Brandi,et al.  Thyroid Cancer: Current Molecular Perspectives , 2010, Journal of oncology.

[15]  M. Xing,et al.  Recent advances in molecular biology of thyroid cancer and their clinical implications. , 2008, Otolaryngologic clinics of North America.

[16]  S. Filetti,et al.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. , 2007, The Journal of clinical endocrinology and metabolism.

[17]  J. Minna,et al.  Methods for detecting DNA methylation in tumors: from bench to bedside. , 2007, Cancer letters.

[18]  P. Vineis,et al.  Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. , 2007, Mutation research.

[19]  M. Xing,et al.  Gene methylation in thyroid tumorigenesis. , 2007, Endocrinology.

[20]  J. Califano,et al.  Increased plasma DNA integrity index in head and neck cancer patients , 2006, International journal of cancer.

[21]  J. Califano,et al.  Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer , 2006, International journal of cancer.

[22]  A. Giuliano,et al.  Prediction of breast tumor progression by integrity of free circulating DNA in serum. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Reber,et al.  Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. , 2006, Clinical chemistry.

[24]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[25]  V. Ganapathy,et al.  Biological functions of SLC5A8, a candidate tumour suppressor. , 2005, Biochemical Society transactions.

[26]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[27]  D. Elashoff,et al.  Allelic Imbalance on 12q22-23 in Serum Circulating DNA of Melanoma Patients Predicts Disease Outcome , 2004, Cancer Research.

[28]  D. Hoon,et al.  Circulating Nucleic Acids and Proteomics of Plasma/Serum: Clinical Utility , 2004, Annals of the New York Academy of Sciences.

[29]  D. Hoon,et al.  Circulating nucleic acids in plasma and serum: past, present and future. , 2004, Current opinion in molecular therapeutics.

[30]  R. Elashoff,et al.  Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. , 2004, Journal of the National Cancer Institute.

[31]  C. Plass,et al.  SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Ladenson,et al.  Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. , 2003, Cancer research.

[33]  M. Stroun,et al.  Circulating nucleic acids in plasma or serum. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[34]  S. Filetti,et al.  Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. , 2001, European journal of endocrinology.

[35]  C. Shriver,et al.  Expression of the Sodium Iodide Symporter and Thyroglobulin Genes Are Reduced in Papillary Thyroid Cancer , 2001, Modern Pathology.

[36]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[37]  M. Yatin,et al.  Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. , 1999, The Journal of clinical endocrinology and metabolism.

[38]  O. Sheils,et al.  TSH receptor status of thyroid neoplasms—TaqMan RT‐PCR analysis of archival material , 1999, The Journal of pathology.

[39]  K. Iczkowski,et al.  Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. , 1998, Pancreas.

[40]  N. Dalay,et al.  Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy , 2008, Clinical chemistry and laboratory medicine.

[41]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.

[42]  F. Borson‐Chazot,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(5):3028–3035 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1394 Silencing of the Tumor Suppressor Gene SLC5A8 Is Associated with BRAF Mutations , 2022 .

[43]  Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology and Biochemistr and Biochemistr and Biochemistr and Biochemistr and Biochemistryyyyy Pendrin: the Thyrocyte Apical Membrane Iodide Transporter? , 2022 .